anti-EGFR antibody [EGFR1]
anti-EGFR antibody [EGFR1] for Flow cytometry,ICC/IF,IHC-Frozen sections,Immunoprecipitation,Western blot and Horse,Human,Mouse
Cancer antibody; Signaling Transduction antibody
Mouse Monoclonal antibody [EGFR1] recognizes EGFR
|Tested Reactivity||Hu, Ms, Hrs|
|Tested Application||FACS, ICC/IF, IHC-Fr, IP, WB|
|Immunogen||Human epidermoid carcinoma line A431|
|Full Name||epidermal growth factor receptor|
|Alternate Names||PIG61; ERBB1; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; NISBD2; Epidermal growth factor receptor; ERBB; HER1; EC 126.96.36.199; mENA|
|Application Note||* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.|
|Calculated MW||175 kDa|
|Purification||Purified by affinity chromatography.|
|Buffer||PBS and 0.02% Sodium azide|
|Preservative||0.02% Sodium azide|
|Storage instruction||For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.|
|Note||For laboratory research only, not for drug, diagnostic or other use.|
|Gene Full Name||epidermal growth factor receptor|
|Background||The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes.|
|Function||Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action. [Uniprot]|
|Research Area||Cancer antibody; Signaling Transduction antibody|
|PTM||Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.
Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B prevents degradation. Ubiquitinated by RNF115 and RNF126 (By similarity).
Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.